Toward a New Standard of Care: Sacituzumab and Pembrolizumab in PD-L1+ mTNBC

In this interview, Dr. Sara Tolaney, MD, MPH, of Dana-Farber Cancer Institute, emphasizes that sacituzumab govitecan + pembrolizumab should become the new standard of care for PD-L1–positive advanced triple-negative breast cancer.